• Cisplatin-Induced Pyroptosis: A New Frontier in Cancer Resea

  2026-04-28

  Explore the unique role of Cisplatin (CDDP) in activating pyroptosis and its implications for cancer research and chemotherapy resistance studies. This article offers advanced insights and practical guidance for leveraging cisplatin in apoptosis and tumor growth inhibition assays.

• Wortmannin: PI3K Inhibitor Workflows for Autophagy & Cancer

  2026-04-28

  Wortmannin empowers researchers to precisely dissect PI3K/Akt/mTOR signaling and autophagy using targeted, robust protocols. Its selectivity and irreversibility set a new benchmark for apoptosis, cancer, and host-pathogen assays—delivering data-driven clarity where off-target effects once clouded results.

• Ferulic Acid Modulates ER Stress to Alleviate Chemotherapy-I

  2026-04-27

  This study demonstrates that ferulic acid mitigates chemotherapy-induced premature ovarian insufficiency (POI) by targeting ER stress pathways in granulosa cells. The findings offer mechanistic insight and translational relevance for apoptosis inhibition and ovarian function preservation in the context of gonadotoxic injury.

• CIAV Hijacks Host CK2α: Mechanisms and Implications for Anti

  2026-04-27

  This study demonstrates that chicken infectious anemia virus (CIAV) requires host casein kinase 2 alpha (CK2α) for efficient replication through a specific interaction with the viral nonstructural protein VP2. By defining the molecular interface and functional consequences of this interaction, the work highlights CK2α as a promising antiviral target and provides a mechanistic framework for future drug development.

• Amikacin (BAY416651): Targeted Delivery and Granuloma Resear

  2026-04-26

  Explore the advanced use of Amikacin (BAY416651) as a bacterial protein synthesis inhibitor, with a focus on its targeted delivery into mycobacterial granulomas. This article delivers a unique, research-driven perspective for antibiotic resistance studies and optimized lab protocols.

• Gut Dysbiosis Drives Prostate Cancer Progression via STAT3 A

  2026-04-25

  Zhong et al. (2022) reveal that gut microbiota disruption accelerates prostate cancer growth and chemoresistance by activating the NF-κB-IL6-STAT3 signaling pathway. Their findings highlight the mechanistic link between antibiotic-induced dysbiosis, increased Proteobacteria, and tumor aggressiveness, providing new directions for targeting STAT3 in cancer biology.

• SEMA3E Drives Beige Adipocyte Thermogenesis via β-Catenin Pa

  2026-04-24

  This study reveals SEMA3E as a novel regulator of beige adipocyte differentiation and thermogenesis in mice, acting through β-catenin signaling. The findings provide mechanistic insight into adipose tissue plasticity and suggest new avenues for metabolic disorder research.

• Ouabain as a Selective Na+/K+-ATPase Inhibitor in Research

  2026-04-24

  Ouabain stands out as a benchmark selective Na+/K+-ATPase inhibitor, enabling precise interrogation of ion transport, cellular signaling, and cardiac function. With robust performance in both cellular and animal models, APExBIO’s ouabain supports reproducible, data-driven advances in cardiovascular and translational research.

• Imeglimin Enhances Mitochondrial Function in CTS-Associated

  2026-04-23

  This study examines the therapeutic potential of Imeglimin in improving mitochondrial function within subsynovial connective tissue (SSCT) cells from patients with idiopathic carpal tunnel syndrome (CTS). The findings demonstrate significant improvements in mitochondrial parameters and reduced cell death, highlighting a promising direction for addressing mitochondrial dysfunction in CTS.

• Brefeldin A: Optimizing ER Stress and Apoptosis Assays in Ca

  2026-04-23

  Brefeldin A (BFA) stands out for its precision in modeling ER stress, dissecting vesicular trafficking, and inducing apoptosis in cancer cells. Harness its unique workflow enhancements and troubleshooting guidance to advance studies in protein quality control and cancer biology.

• Annexin V-FITC/PI Apoptosis Assay Kit: Technical Guide

  2026-04-22

  The Annexin V-FITC/PI Apoptosis Assay Kit (SKU K2003) enables rapid, reliable detection and staging of apoptosis in cell populations by distinguishing viable, early apoptotic, and late apoptotic/necrotic cells. It is best suited for research workflows using flow cytometry or fluorescence microscopy where precise quantification of cell death stages is required. This product is not intended for diagnostic or clinical use and should not be applied outside of research contexts.

• Minoxidil Sulphate: Translating Potassium Channel Science

  2026-04-22

  This thought-leadership article explores how Minoxidil sulphate, the active metabolite of minoxidil, is catalyzing advances in translational research spanning vascular biology and hair follicle science. By integrating mechanistic insights into potassium channel pharmacology, evidence from peer-reviewed studies, and strategic workflow guidance, we chart a path for researchers to leverage high-purity Minoxidil sulphate from APExBIO in experimental design. This piece goes beyond standard product pages by critically evaluating recent findings, addressing experimental challenges, and providing a forward-looking perspective on clinical and translational impact.

• Cisplatin in Cancer Immunomodulation: Mechanistic Insights &

  2026-04-21

  Explore the dual role of Cisplatin (CDDP) in cancer research and immunomodulation, with unique focus on PD-L1 regulation via ER stress pathways. This article delivers advanced, evidence-driven guidance for designing apoptosis and chemoresistance studies with APExBIO’s Cisplatin.

• Haloprogin: Mechanistic Insights and Protocol Optimization

  2026-04-21

  Explore the advanced mechanism and research protocol optimization of Haloprogin, a leading broad-spectrum antifungal agent. This article provides unique, evidence-driven guidance for maximizing Haloprogin’s utility in contemporary infection models.

• First-Line Topotecan and Cisplatin in Small Cell Lung Cancer

  2026-04-20

  This article analyzes the clinical evidence for topotecan-based regimens as first-line therapies in small cell lung cancer (SCLC), with a focus on the benchmark role of cisplatin (CDDP) in standard combination protocols. The review discusses the study's nuanced evaluation of therapeutic efficacy, toxicity, and the clinical implications for optimizing apoptosis assays and chemoresistance studies.

15614 records 1/1041 page Next 12345 下5页 Last page